**Abstracts**

**DOES ROBOTIC SURGERY IMPROVE SURGICAL OUTCOMES AND SURVIVAL COMPARED TO CONVENTIONAL LAPAROSCOPY IN GYNECOLOGICAL CANCER?**

Myriam Grazia, Ignacio Zapardiel, Miguel Angel Herráiz, Javier García, Mar Ramírez, Monica Bellon, Flavio Coronado, La Paz University Hospital, Madrid, Spain; Clinico San Carlos University Hospital, Madrid, Spain

10.1136/ijgc-2022-ESGO.436

**INTRODUCTION/BACKGROUND**

Several scientific publications that compare robotic and conventional laparoscopy surgery reveal some advantages for the patient of robotic surgery in certain gynecological procedures and pathologies. However, some authors consider the use of the surgical robot inefficient. Our aim is to evaluate whether robotic surgery could be a real benefit in terms of perioperative outcomes and morbidity without affecting oncological safety.

**METHODOLOGY**

Data from 534 patients were collected, 347 of them were operated by robotic surgery (RS) and 187 by conventional laparoscopic approach (CL). A comparative study between both approaches was performed in a tertiary hospital from 2007 to 2019. Patients with endometrial, ovarian and cervical carcinoma were included. Basic demographic characteristic, surgical outcomes, morbidity and survival were compared. Procedures performed were hysterectomy with double adnexectomy, hysterectomy with lymphadenectomy (pelvic or pelvic and para-aortic), radical hysterectomy and para-aortic lymphadenectomy.

**RESULTS**

Total operation time was significantly longer in patient operated by robotic surgery (RS 209 minutes vs. 191 min CL; p=0.006). Blood loss was reduced in patients operated by robotic approach (RS 112 ml vs. CL 136 ml; p=0.020). No differences were found in hospital stay, number of pelvic or paraaortic nodes, laparotomic conversion or reintervention rate and intra or postoperative complications between both surgical approaches. Overall survival was similar in both surgical approaches although disease free survival was 85% in the robotic group and 90.7% in the laparoscopic group (HR: 0.47; IC95%:0.26–0.86; p=0.015). In a multivariate analysis the only independent factor related to disease free survival was FIGO stage.

**CONCLUSION**

Robotic surgery and conventional laparoscopy surgery are comparable in terms of perioperative morbidity, conversion rate, hospital stay, number of nodes obtained, or overall survival. Robotic surgery increases total operative time and reduces intraoperative bleeding compared to laparoscopy.

**2022-RA-1144-ESGO MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH SOLID TUMOURS TREATED WITH DOSTALIMAB IN THE GARNET STUDY**

Dominique Bertot, Thierry Andre, Ana Oknirin, Victor Moreno, Jose Trigo, Giuseppe Curigliano, Anna V Tinker, Valentina Boni, Maria Pillar Barettina-Ginesta, Joanna Pikiel, Bhavana Potthuri, Mansoor R Mirza, Petra Panovcova, Tao Duan, Christine Dabrowski, Christine Dabrowski, Eythlethiros Zografos, Jennifer Veneris, NEXT Oncology Hospital Universitario Quironsalud, Affiliation at time of study, Current affiliation. GINECO and Institut de Cancerologie de l'Ouest, Centre René Gauduchet, Saint-Herblain, France; Sorbonne University and Saint-Antoine Hospital, Paris, France; Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; START Madrid-FD, Fundación Jiménez Diaz Hospital, Madrid, Spain; Medical Oncology Department, Hospital Vélez de la Victoria IBIMA, Málaga, Spain; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, and University of Milano, Milan, Italy; Department of Medicine, British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain; Department of Medical Oncology, Catalan Institute of Oncology (ICO) Girona, Girona Biomedical Research Institute (IDIBGI), Department of Medical Sciences, Medical School University of Girona (UdG), Girona, Spain; Department of Chemotherapy, Regional Center of Oncology, Gdansk, Poland; Gynecologic Oncology Group (GOG) and Department of Obstetrics/Gynecology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, Denmark; Nemocnice Horovice, Horovice, Czech Republic; GSK, Pennington, NJ; GSK, Walheim, MA; GSK, London, UK; Gynaecologic Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK

10.1136/ijgc-2022-ESGO.437

**INTRODUCTION/BACKGROUND**

Dostalimab is an approved programmed death 1 (PD-1) inhibitor. PD-1 therapy can lead to immune-related adverse events (irAEs). Here we report on the management of irAEs across multiple tumour types evaluated in GARNET.

**METHODOLOGY**

GARNET is a multicentre, open-label, single-arm phase 1 study with dose expansion in multiple tumour types: mismatch repair deficient solid tumours, mismatch repair proficient endometrial cancer, non-small cell lung cancer, and platinum-resistant ovarian cancer. Patients received 500 mg of dostalimab intravenously Q3W for 4 cycles, then...